A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany
Authors:
Open Access
- 9 April 2016
- journal article
- research article
- Published by Springer Nature in Infection
- Vol. 44 (5) , 599-606
Abstract
Purpose Clostridium difficile infection (CDI) represents a significant economic healthcare burden, especially the cost of recurrent disease. Fidaxomicin produced significantly lower recurrence rates and higher sustained cure rates in clinical trials. We evaluated the cost-effectiveness and budget impact of fidaxomicin compared with vancomycin in Germany in the first-line treatment of patient subgroups with CDI at increased risk of recurrence. Methods A semi-Markov model was used to compare the cost-effectiveness and budget impact of fidaxomicin vs. vancomycin from a payer perspective in Germany. The model cycle length was 10 days. The time horizon was 1 year. Model inputs were probability of clinical cure, 30-day probability of recurrence, and 30-day attributable mortality based on evidence from two randomized controlled trials comparing fidaxomicin and vancomycin in patients with CDI. Cost-effectiveness outcomes were cost per quality-adjusted life year gained, cost per bed-day saved, and cost per recurrence avoided. Results Despite higher drug acquisition costs, fidaxomicin was dominant in the cancer subgroup (less costly and more effective) and cost-effective in the other subgroups, with incremental cost-effectiveness ratios vs. vancomycin ranging from €26,900 to €44,500. Hospitalization costs of the first-line treatment of CDI with fidaxomicin vs. vancomycin were lower in every patient subgroup, resulting in budget impacts ranging from −€1325 (in patients ≥65 years) to −€2438 (in cancer patients). Reductions in the cost of treating recurrence with fidaxomicin ranged from −€574.32 per patient in those receiving concomitant antibiotics to −€1500.68 per patient in renally impaired patients. Conclusions In patient subgroups with CDI at increased recurrence risk, fidaxomicin was cost-effective vs. vancomycin, and less costly and more effective in patients with cancer.Keywords
Funding Information
- Astellas Pharma Europe
This publication has 35 references indexed in Scilit:
- Renal Impairment and Clinical Outcomes of Clostridium difficile Infection in Two Randomized TrialsAmerican Journal of Nephrology, 2013
- Clostridium difficile Infection: New Insights Into ManagementMayo Clinic Proceedings, 2012
- Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled TrialsClinical Infectious Diseases, 2012
- Predictors of First Recurrence of Clostridium difficile Infection: Implications for Initial ManagementClinical Infectious Diseases, 2012
- Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infectionJournal of Hospital Infection, 2012
- Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trialThe Lancet Infectious Diseases, 2012
- Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent InfectionsClinical Infectious Diseases, 2011
- Treatment with Monoclonal Antibodies againstClostridium difficileToxinsNew England Journal of Medicine, 2010
- Single- Versus Multiple-Dose Antibiotic Prophylaxis in the Surgical Treatment of Closed Fractures: A Meta-AnalysisJournal of Orthopaedic Trauma, 2008
- Emergence of Clostridium difficile-associated disease in North America and EuropeClinical Microbiology and Infection, 2006